Stifel Financial Corp Has $1.65 Million Holdings in Elanco Animal Health Incorporated (NYSE:ELAN)

Stifel Financial Corp raised its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 82.4% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 112,102 shares of the company’s stock after purchasing an additional 50,637 shares during the period. Stifel Financial Corp’s holdings in Elanco Animal Health were worth $1,647,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Canada Pension Plan Investment Board purchased a new position in Elanco Animal Health during the second quarter worth about $55,599,000. Magnetar Financial LLC boosted its stake in shares of Elanco Animal Health by 61.2% in the 2nd quarter. Magnetar Financial LLC now owns 8,336,657 shares of the company’s stock worth $120,298,000 after buying an additional 3,164,350 shares during the last quarter. Point72 Asset Management L.P. bought a new position in shares of Elanco Animal Health in the third quarter valued at approximately $19,708,000. Assenagon Asset Management S.A. increased its position in shares of Elanco Animal Health by 363.1% during the third quarter. Assenagon Asset Management S.A. now owns 1,548,506 shares of the company’s stock valued at $22,748,000 after acquiring an additional 1,214,123 shares during the last quarter. Finally, Great Lakes Advisors LLC bought a new stake in Elanco Animal Health during the second quarter worth $16,043,000. 97.48% of the stock is owned by institutional investors.

Elanco Animal Health Trading Down 1.6 %

Shares of ELAN stock opened at $11.63 on Friday. The stock has a market capitalization of $5.75 billion, a price-to-earnings ratio of 29.08, a PEG ratio of 2.03 and a beta of 1.41. The company’s fifty day simple moving average is $13.02 and its two-hundred day simple moving average is $14.19. Elanco Animal Health Incorporated has a 1 year low of $11.40 and a 1 year high of $18.80. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.12 by $0.01. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The company had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.04 billion. During the same period in the previous year, the company posted $0.18 EPS. The firm’s revenue for the quarter was down 3.6% compared to the same quarter last year. As a group, analysts anticipate that Elanco Animal Health Incorporated will post 0.92 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Leerink Partners initiated coverage on Elanco Animal Health in a research note on Monday, December 2nd. They issued a “market perform” rating and a $14.00 price objective for the company. Leerink Partnrs upgraded shares of Elanco Animal Health to a “hold” rating in a report on Monday, December 2nd. Morgan Stanley lowered shares of Elanco Animal Health from an “overweight” rating to an “equal weight” rating and lowered their price objective for the stock from $17.00 to $15.00 in a research report on Thursday, September 19th. UBS Group initiated coverage on shares of Elanco Animal Health in a research report on Monday, December 9th. They set a “buy” rating and a $18.00 target price for the company. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $20.00 price target on shares of Elanco Animal Health in a report on Thursday, September 19th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $16.71.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.